SHARESIFT
Healthcare · data ~15-min delayed
144.3 USD +0.34%
| Price | 144.3 USD |
| Day change | +0.34% |
| Market cap | 356.01B |
| 52-week range | 82.01 – 156.92 |
| P/E (trailing) | 114.5 |
| Dividend yield | 2.36% |
| Payout ratio | 268.80% |
| Return on equity | 6.96% |
| Debt / equity | 128% |
| Beta | 0.23 |
| Sector | Healthcare |
| Value score | 10 / 100 |
Merck & Co., Inc. (MRK) scores 10/100 on this site's value model, in the lower band: most of the valuation measures it checks sit on the richer side. It trades at 114.5 times trailing earnings and is classified in Healthcare. The dividend yield is 2.36%, paid from 269% of earnings. Return on equity is 7%, with debt at 128% of equity. On its filings it passes 5 of the nine Piotroski checks, a mixed picture. Its Altman Z-Score places it in the safe zone. These are automated readings of reported figures, not a recommendation.
Piotroski F-Score 5 / 9 — nine pass/fail checks on profitability, leverage and efficiency, comparing the latest financial year with the one before.
Altman Z-Score 4.44 — Safe zone.
Updated · prices ~15-min delayed, fundamentals as last reported
Open full interactive analysis →See how it ranks: US stocks by value score
Value scoring · Piotroski F-Score · Altman Z · technicals · dividends — free, no sign-up.